Copyright
©The Author(s) 2015.
World J Biol Chem. Aug 26, 2015; 6(3): 162-208
Published online Aug 26, 2015. doi: 10.4331/wjbc.v6.i3.162
Published online Aug 26, 2015. doi: 10.4331/wjbc.v6.i3.162
Table 1 Roles and targets of the myomiRs, miR-1, -206, -133a, -133b
Factor(s) | Regulation | Regulator | Tissue/cell | Ref. |
Fish and lower vertebrates: Development and regeneration | ||||
Ttk protein kinase (mps1) | Upregulated mps1: a target of miR-133 | Downregulation of miR-133 by Fgf | Regeneration of Zebrafish caudal fin (appendage) | [68] |
RhoA | Downregulation of RhoA mRNA | Upregulation of miR-133b expression | Regenerating adult zebrafish spinal cord, axon outgrowth | [69] |
RhoA | Downregulation of RhoA protein | Upregulation of miR-1 and miR-133 expression | Zebrafish muscle gene expression and regulation of sarcomeric actin organization | [166] |
Cell cycle factors mps1, cdc37 and PA2G4, and cell junction components cx43 and cldn5 | Upregulated mps1, cdc37, PA2G4, cx43, cldn5 | Downregulated miR-133(a1) stimulates cardiac cell regeneration | Regenerating zebrafish cardiac muscle | [167] |
miR-133b | MiR-133b found in developing somites, little in CNS tissues | Whole zebrafish embryos - normal development | [168] | |
SRF activates muscle specific genes and miRs; | MiR-1 targets HDAC4, promoting myogenesis | In contrast, miR-133a represses SRF, enhancing myoblast proliferation | X. laevis embryos: skeletal muscle proliferation and differentiation in cultured myoblasts in vitro and in embryos in vivo | [7] |
HDAC4 represses muscle gene expression | ||||
nAChR subunits UNC-29, UCR-63; MEF2 | Subunits UNC-29, UCR-63, and MEF2 downregulated | miR-1 upregulated | C. elegans muscle at the neuromuscular junction | [34] |
Mammalian pluripotent cells | ||||
Muscle-specific microRNAs: miR-1 and miR-133a | MiR-1 and miR-133a have opposing functions during differentiation of progenitor cardiac muscles | Muscle-specific | Promotion of mesoderm formation from mouse ES cells | [13] |
microRNAs, miR-1 and miR-133(a) upregulated | ||||
Notch signalling, promotes neural differentiation and inhibits muscle differentiation; opposes miR-1 effects | Dll-1 translationally repressed | miR-1 upregulation, promotes cardiomycete differentiation | Mouse and human ES cell differentiation into muscle | [13] |
SRF-/- EBs reflecting the loss of hematopoietic lineages in the absence of SRF | Early endoderm markers, Afp and Hnf4α: strongly down regulated | Increased miR-1 and miR-133a relieve the block on mesodermal differentiation | Mouse endoderm | [13] |
Blood cell -specific genes, such as Cd53, CxCl4, and Thbs1, dramatically down regulated | Cd53, CxCl4, and Thbs1 expression was reinitiated by reintroduction of miR-1 or miR-133 | |||
mES(miR-1)- and mES(miR-133a)- EBs compared to in control EBs | Nodal stimulated expression of endoderm markers Afp and Hnf4α in control EBs. Dramatically lower levels in mES(miR-1)- and mES(miR-133a)- EBs | miR-1 or miR-133 can each function as potent repressors of endoderm gene expression | mES cells, that lack either miR-1 or miR-133(a) during differentiation into EBs | [13] |
IGF-1 | IGF-1 signalling and miR-133 co-regulate myoblast differentiation via a feedback loop | IGF-1 upregulates miR-133; | Myogenic differentiation of C2C12 myoblasts; Mouse during development from embryonic to mature skeletal muscle | [24] |
IGF-1R | miR-133 downregulates IGF-1R | |||
IGF-1 | IGF-1 signalling and miR-1 coregulate differentiation of myoblasts via a feedback loop | IGF-1 signalling downregulates miR-1 by repression of FoxO3a; | Differentiating C2C12 myoblasts | [25] |
miR-1 down-regulates IGF-1 | ||||
Reversine [2-(4-morpholinoanilino)-N6-cyclohexyladenine] | Decrease in active histone modifications; including trimethylation of histone H3K4/ H3K36, phosphorylation of H3S10; | miR-133a expression strongly inhibited by reversine; reduced acetylation of H3K14 at miR-133a promoter | Reversine dedifferentiates murine C2C12 myoblasts back into multipotent progenitor cells, via extensive epigenetic modification of histones resulting in chromatin remodelling, and altered gene expression | [20-23] |
Stimulates expression of polycomb genes Phc1 and Ezh2 | Reduced expression of myogenin, MyoD, Myf5 and Aurora A and B kinases | |||
FZD7 and FRS2 | miR-1 promotes cardiac differentiation; miR-1 targets FZD7 and FRS2 | Activitation of WNT and signalling cause MCPs differentiation into cardiomyocytes | Mouse and human ES cells | [169] |
miR-206/133b cluster | PAX7 gene expression unchanged; | miR-206/133b cistron knock-out mice cells | Muscle satellite cell differentiation in vitro | [170] |
miR-206/133b cluster is not required for development, and survival of skeletal muscle cells | ||||
Differentiating skeletal muscle | ||||
DNA polymerase alpha | Repression of Idl-3 protein expression | miR-206 up-regulated | Mouse skeletal muscle differentiation | [42] |
Repression of p180 subunit of DNA polymerase alpha | ||||
MEF2 transcription factor | MEF2 activates of miR-1-2 and 133a-1 transcription; binds muscle-specific enhancer | Bicistronic primary transcript of miR-1-2 and 133a-1 | Development of mammalian skeletal muscle | [9] |
MRFs, Myf5, MyoD, Myogenin and MRF4 | Myf5 essential for miR-1 and miR-206 expression during skeletal muscle myogenesis | Forced expression of MRFs in neural tube induces miR-1 and miR-206 expression | Chicken and mouse embryonic muscle | [171] |
PTB and neuronal homolog nPTB, exon splicing factors | Downregulation of PTB protein by miR-133 (and miR-206) | Concurrent upregulation of miR-133 and induction of splicing of several PTB-repressed exons | During myoblast differentiation, microRNAs control a developmental exon splicing program | [172] |
BDNF | BDNF downregulated | miR-206 upregulated | Differentiation of C2C12 myoblasts into myotubes | [48] |
Fstl1 and Utrn | Fstl1 and Utrn downregulated | miR-206 upregulated | Skeletal muscle differentiation | [40] |
Utrophin A (muscle) | Utrophin A down-regulated by both miRs | Upregulated miR-133b, miR-206 | C2C12 mouse myoblasts, mouse soleus muscle | [173] |
CNN3 gene | Negative correlation between miR-1 expression and CNN3 mRNA expression | Normal skeletal muscle | Tongcheng (Chinese) and Landrace (Danish) pigs | [174] |
FGFR1 and PP2AC, members of ERK1/2 signalling pathway | miR-133 (a and b) activities increase during myogenesis | miR-133 directly downregulates expression of FGFR1 and PP2AC | Mouse C2C12 myoblast cells | [31] |
ERK1/2 signalling pathway activity | ERK1/2 signalling activity suppresses miR-133 expression | Downregulation of expression of miR-133 | A reciprocal mechanism for regulating myogenesis | |
BAF chromatin remodelling complex (BAF60a, BAF60b and BAF60c) | Positive inclusion of BAF60c in the BAF chromatin remodeling complex | Expression of miR-133 and miR-1/206 | Progression of developing somites in chick embryos | [63] |
BAF chromatin remodelling complex | Negative regulation of BAF60a and BAF60b; exclusion from BAF chromatin remodelling complex | Expression of miR-133 | Progression of developing somites in chick embryos | [63] |
BAF chromatin remodelling complex | Exogenous upregulation of BAF60a and BAF60b | Delay in developing somites in chick embryos | [63] | |
Mitochondrial UCP2 and UCP3 | MyoD activates miR-133a expression which in turn directly downregulates UCP2 mRNA | Feedback network involving MyoD-miR-133a-UCP2 | Mouse skeletal and cardiac muscles; UCP2 imposes developmental repression | [56] |
Mitochondrial UCP2 and UCP3 | Exogenous overexpression of myogenin and MyoD transcription factors | Strong increase in UCP3 promoter, expression, weak effect at the UCP2 promoter | Mouse C2C12 myoblasts | [57] |
Proliferating myogenic skeletal muscle cells | ||||
MiR-206/133b cluster | MiR-206/133b cluster is not required for survival and regeneration of skeletal muscle | Muscle regeneration proceeds in Mdx mice in vivo | miR-206/133b cistron knock-out mice | [170] |
Enhanced translation of specific mitochondrial genome-encoded transcripts | miR-1 enters muscle mitochondria and binds mtRNA targets along with Ago factor | Increased expression of mtRNA targets | Proliferating myogenic skeletal muscle cells after muscle injury | [53] |
mTOR (serine/threonine kinase) | MyoD stability regulated by mTOR | Regulates miR-1 expression via MyoD availability | Regenerating mouse skeletal muscle and differentiating myoblast cells | [32] |
AMPK-CRTC2-CREB and Raptor-mTORC-4EBP1 pathways | mTORC regulates timing of satellite cell proliferation during myogenesis | Knockdown of mTORC reduces miR-1 expression | Myogenenic satellite SCs proliferating and differentiating into myogenic precursors following rat skeletal muscle injury | [58] |
HDAC4 regulates Pax7-dependent muscle regeneration | Pax7 stimulates SCs differentiation toward the muscle lineage, and limits adipogenic differentiation | HDAC4 upregulated in SCs differentiating into muscle cells | Myogenenic satellite SCs | [175] |
pcRNA encoded by the H strand of the rat mitochondrial genome | Introduction of mt pcRNAs into injured muscle restoring mitochondrial mRNA levels; Intramuscular ATP levels were elevated after pcRNA treatment of injured muscle | Enhanced organellar translation and respiration; similarly reactive oxygen species were reduced; Resulted in accelerated rate of wound resolution | Injured rat skeletal muscle is associated with general downregulation of mitochondrial function; reduced ATP, and increased ROS | [176] |
Cardiac muscle precursor cells | ||||
GATA binding protein 4, Hand2, T-box5, myocardin, and microRNAs miR-1 and miR-133 | Reprogrammed human fibroblasts show sarcomere-like structures and calcium transients; Some cells have spontaneous contractility | Forced over-expression of GATA binding protein 4, Hand2, T-box5, myocardin, and microRNAs miR-1 and miR-133 | Human embryonic and adult fibroblasts activated to express cardiac markers | [15] |
SRF, MyoD and Mef2 transcription factors | miR-1-1 and miR-1-2 | miR-1 genes upregulated; | Cardiac muscle precursor cells | [30] |
During cardiogenesis miR-1 genes titrate critical cardiac regulatory proteins, control ratio of differentiation to proliferation | Elevated miR-1 targets downregulation of Hand2 | |||
Histone deacetylase inhibitor, trichostatin A forces differentiation, yet reduced miR-1 and miR-133a | miR-1 and miR-133a reduce cardiac specific Nkx2.5 protein and Cdk9 | miR-1 and miR-133a increase during spontaneous differentiation of cardiac myoblasts | Mouse cardiac stem cells (ES cells) | [10] |
Specific inhibition of HDAC4 modulates CSCs to facilitate myocardial repair | Positively proliferative myocytes increased in MI hearts receiving HDAC4 downregulated CSCs | CSCs with downregulated HDAC4 expression improved ventricular function, attenuated ventricular remodeling, promoted regeneration and neovascularization in MI hearts | Mouse CSCs transplanted into MI mouse hearts | [177] |
Snai1 | Overexpression of miR-133a (miR-133), Gata4, Mef2c, and Tbx5 (GMT) or GMT plus Mesp1 and MyocD improved cardiac cell reprogramming from mouse or human fibroblasts | miR-133a directly represses Snai1 expression, which silences fibroblast signatures; a key molecular process during cardiac reprogramming | Mouse/human fibroblasts more efficiently reprogrammed into cardiomycete-like cells | [16] |
β1AR signal transduction cascade | Adenylate cyclase VI and the catalytic subunit of the cAMP-dependent PKA are components of β1AR transduction cascade | miR-133 directly targets β1AR, Adenylate cyclase VI and PKA | TetON-miR-133 inducible transgenic mice, subjected to transaortic constriction, maintained cardiac performance with attenuated apoptosis and reduced fibrosis via elevated miR-133 expression | [17] |
ROS, MDA, SOD and GPx | miR-133 produced a reduction of ROS and MDA levels, and an increase in SOD activity and GPx levels | Overexpression of miR-133, a recognized anti-apoptotic miRNA | In vitro rat cardiomyocytes | [18] |
Caspase-9 | miR-133 directly suppresses caspase-9 expression resulting in downregulation of downstream apoptotic pathways | Overexpression of miR-133 | In vitro rat cardiomyocytes | [18] |
Spred1 | miR-1 directly targets Spred1 | miR-1 is upregulated in hCMPCs during angiogenic differentiation | hCMPCs | [178] |
miRNA-1 and miRNA-133a | miRNA-1 and miRNA-133a have antagonistic roles in the regulation of cardiac differentiation | Forced overexpression of miR-1 alone enhanced cardiac differentiation, in contrast overexpression of miR-133a reduced cardiac differentiation, compared to control cells | Pluripotent P19.CL6 stem cells | [179] |
Overexpression of both miRNAs promoted mesodermal commitment and decreased expression of neural differentiation markers | ||||
Cardiac muscle | ||||
Induction of GATA6, Irx4/5, and Hand2 | Cardiac myocytes show defective heart development, altered cardiac morphogenesis, channel activity, and cell cycling | miR-1-2-/- gene knockout | Cardiac myocytes with knockout of both miR-1-2 genes | [180] |
mt-COX1 mRNA | 3’-UTR of mt-COX1 mRNA bound by miR-181c and Ago1 factor | Overexpression of miR-181c significantly decreased mt-COX1 protein, but not mt-COX1 mRNA level | Overexpression of miR-181c increased mitochondrial respiration and reactive oxygen species in neonatal rat ventricular myocytes | [54] |
mt-COX1 mRNA | In vivo elevation of miR-181c in rat heart, reduces levels of mt-COX1 protein | Results in reduced capacity for strenuous exercise and evidence of heart failure | Rat cardiac muscle | [55] |
Carvedilol, a β-adrenergic blocker | Induces upregulation of miR-133 | Cytoprotective effects against cardiomyocyte apoptosis | Rat cardiac tissue, in vivo | [18] |
GLUT4, and SRF | Both miRs downregulate SRF and KLF15 | Both miR-133a and miR-133b target KLF15 | Mouse cardiac myocytes | [181] |
GLUT4 expression | Both basal and insulin-stimulated glucose uptake are increased | KLF15 | Mouse muscle cell lines | [182] |
MEF2 transcription factor | MEF2 directly activates transcription of miR-1-2 and 133a-1 binding muscle-specific enhancer between the genes | Bicistronic primary transcript of miR-1-2 and 133a-1 | Development of mammalian cardiac muscle | [9] |
Myocardium tissue | Enriched in miR-1, miR-133b, miR-133a | Heart structures of rat, Beagle dog and cynomolgus monkey | [183] | |
Gelsolin | One common miR-133a isomiR targets gelsolin gene more efficiently than standard isomer; New second rat miR-1 gene | Many isomiRs were detected by deep sequencing at higher frequency than the canonical sequence in miRBase | miRNA/isomiR expression profiles in the left ventricular wall of rat heart | [184] |
CTGF | CTGF downregulated by both miRs | Exogenous upregulation of miR-133b (and miR-30c) | Cultured cardiomyocytes and ventricular fibroblasts | [185] |
MT1-MMP | miR-133a upregulated | miR-133a targets MT1-MMP | Human left ventricular fibroblasts | [186] |
Injured and regenerating cardiac muscle | ||||
SERCA2a | Akt/FoxO3A-dependent pathway | Downregulation of miR-1 expression in failing heart muscle | Failing mouse heart muscle | [187] |
Activated SERC2a reduces phosphorylation of FoxO3a, allowing entry to nucleus and activation of miR-1 expression | ||||
IGF-1 | IGF-1 signalling and miR-1 co-regulate differentiation of myoblasts via a feedback loop | IGF-1 signalling down-regulates miR-1 by repression of FoxO3a; | Mouse heart muscle during cardiac failure states | [25] |
miR-1 down-regulates IGF-1 | ||||
Bim and Bmf | Only miR-133a expression enhanced under in vitro oxidative stress | miR-133a targets proapoptotic genes Bim and Bmf | Rat adult CPCs | [188] |
miR-1 favors differentiation of CPCs, whereas | ||||
Bim and Bmf | CPCs overexpressing miR-133a improved cardiac function by reducing Bim and Bmf | CPCs overexpressing miR-133a improved cardiac function, increasing vascularization and cardiomyocyte proliferation, reduced fibrosis and hypertrophy | CPCs overexpressing miR-133a in rat myocardial infarction model | [188] |
MT1-MMP activity increased in both. Ischemia and reperfusion regions | Interstitial miR-133a decreased with ischemia in vitro and in vivo; reperfusion returned to steady-state | Phosphorylated Smad2 increased within the ischemia-reperfusion region | Ischemia-reperfusion Yorkshire pigs (90 min ischemia/120 min reperfusion) | [186] |
Cardiovascular disease | ||||
CNN2 | Strong upregulation of CNN2 expression | miR-133b downregulated; miR-133b directly targets CNN2 | Pre-inflammatory events in diseased cardiac tissues | [65] |
Circulating platelet derived microparticles | Elevated miR-133 | Patients with stable and unstable coronary artery disease | [189] | |
Acute MI causes upregulation of circulating serum miRs | miR-1, -133a, -133b, and -499-5p were about 15- to 140-fold elevated over control | Acute STEMI patients and experimental mouse MI model | [190] | |
Circulating miRNAs in serum of cardiovascular disease patients | Released miR-1 and miR-133a are localized in exosomes, and are released by Ca(2+) stimulation | Levels of miR-1, miR-133a, reduced in infarcted mouse myocardium model heart | miR release indicates myocardial damage | [191] |
LVM after valve replacement in aortic stenosis | microRNA-133a is a significant positive predictor of LVM normalisation | miR-133 is a key element of the reverse remodelling process | Patients following valve replacement | [192] |
Circulating levels of miR-133a | Elevated miR-133a (11-fold) | Troponin-positive acute coronary syndrome patients | [193] | |
Circulating levels of miR-133a | Elevated miR-133a | Improved potential regression of Left Ventricular Hypertrophy after valve replacement | Patients with aortic stenosis surgery | [194] |
Apelin treatment reduces elevated circulating miRs | Elevated miR-133a, miR-208 and miR-1 reduced | High-fat diet elevated miRs and increased left ventricular diastolic and systolic diameters, and wall thickness | Obesity-associated cardiac dysfunction in mouse model | [195] |
NAC treatment | Expressed miR-1, miR-499, miR-133a, and miR-133b were strongly depressed in the diabetic cardiomyocytes | NAC restored expression of miR-499, miR-1, miR-133a, and miR-133b significantly in the myocardium | Diabetic rat hearts | [196] |
Myocardial junctin elevated | miR-1 targets junctin | NAC reduces junction levels | Development of diabetic cardiomyopathy in rat hearts | [196] |
CAD associated ischemic heart failure | miR-133 expression decreased with increased severity of heart failure | Patients with CAD | [197] | |
Runx2 | miR-133a targets Runx2 | Transition of VSMCs to osteoblast-like cells | [198] | |
Increased alkaline phosphatase activity, osteocalcin secretion and Runx2 expression | miR-133a was decreased during osteogenic differentiation | Transition of VSMCs to osteoblast-like cells | [198] | |
Circulating miR-133a and 208a levels | Cardiac muscle-enriched microRNAs (miR-133a, miR-208a) elevated | Patients with coronary artery disease | [199] | |
Hypertrophic cardiac muscle | ||||
Cx43 increased | miR-1 targets Cx43 | Downregulation of miR-1 mediates induction of pathologic cardiac hypertrophy | Hypertrophic rat cardiomyocytes in vitro and in vivo | [200] |
Cx43 downregulated | miR-1 targets Cx43 | Cx43 protein downregulated in miR-1 Tg mice compared to WT mice | Cardiac-specific miR-1 transgenic (Tg) mouse model | [201] |
Twf1 upregulated | miR-1 targets Twf1 | Strong downregulation of miR-1 in pathologic hypertrophic cardiac cells compared to normal, induces Twf1 expression | In vivo in hypertrophic mouse left ventricle; and in vitro in phenylephrine-induced hypertrophic cardiomyocytes | [202] |
RhoA, Cdc42, Nelf-A/WHSC2 | Increased levels of RhoA, Cdc42, Nelf-A/WHSC2 | Reduction miR-133a | Hypertrophic cardiac muscle | [6] |
Calcineurin, agonist of cardiac hypertrophy | Increased Calcineurin activity; | Reduced miR-133a; | Hypertrophic cardiac muscle; | [203] |
Cyclosporin A inhibits calcineurin | Prevents miR-133 down-regulation | Cardiac hypertrophy reduced | ||
NFATc4 | NFAFc4 targetted by miR-133a | miR-133a | Cardiomyocyte hypertrophic repression | [204] |
Interdependent Calcineurin-NFAT and MEK1-ERK1/2 signalling pathways in cardiomyocytes | MEK1-ERK1/2 signalling augments NFAT and NFAF gene expression; Activated calcineurin activates NFAT, inducing cardiac hypertrophy | MEK1 is part of mitogen-activated protein kinase (MAPK) cascade; MEK1 activates ERK directly | Hypertrophic growth response of mouse cardiomyocytes | [205] |
Innervating skeletal muscle | ||||
Innervated skeletal muscle | MyoD, Myf5, Mrt4, nAChRα | Myogenin expression | Mouse skeletal muscle | [50,51] |
Each is strongly repressed | ||||
Denervated muscle (unstimulated) | Myogenin expression up-regulated MyoD, Myf5, Mrt4, nAChRα | Mouse skeletal muscle | [51] | |
All strongly stimulated | ||||
Electrically stimulated - Denervated muscle | Myogenin, MyoD, Myf5, Mrt4, partly stimulated; nAChRα inhibited | Mouse skeletal muscle | [51] | |
HDAC4 | miR-1 promotes myogenesis by targetting HDAC4 | miR-133 enhances myoblast proliferation by targetting SRF | Skeletal muscle proliferation and differentiation in myoblast cultures | [7] |
SRF | ||||
Neural activity effect on muscle (HDAC4 - MEF2 Axis) | Loss of neural input leads to concomitant nuclear accumulation of HDAC4 | HDAC4 inhibits activation of muscle transcription factor MEF2; results in progressive muscle dysfunction | MEF-2 activity strongly inhibited in denervated mouse skeletal muscle and in ALS muscle | [49] |
Innervation and formation of airway smooth muscle | Sonic hedgehog (Shh) /miR-206/ BDNF | Shh signalling blocks miR-206 expression, which in turn increases BDNF protein | Shh coordinates innervation and formation of airway smooth muscle | [206] |
nAChR subunits (UNC-29 and UNC-63); retrograde signalling | Subunits UNC-29, UCR-63 and MEF2 downregulated | miR-1 upregulated | C. elegans muscle at the neuromuscular junction | [34] |
MEF2 | Hnrpu, Lsamp, MGC108776, MEF2, Npy, and Ppfibp2 downregulated | miR-206 upregulated | Rat skeletal muscle/re-innervating muscle | [43] |
HDAC4 | HDAC4 (miR-206 target, prospective miR-133b target) downregulated | miR-206/-133b upregulated (and miR-1/-133a downregulated) | Mouse fast twitch skeletal muscle/re-innervating muscle | [12] |
Regenerating injured muscle | ||||
Hnrpu and Npy downregulated | miR-1 upregulated | miR-1, -133a, downregulated 1 mo after denervation, then increased 2 × at 4 mo after re-innervation | Rat skeletal soleus muscle after sciatic nerve injury and subsequent re-innervation | [43] |
Ptprd downregulated | miR-133a upregulated | |||
Hnrpu, Lsamp, MGC108776, MEF2, Npy, and Ppfibp2 downregulated | 3 × increase in miR-206 1 mo later, after reinnervation; elevated at least 4 mo | Predominant type II fiber at 4 mo, after nerve re-innervation | Rat skeletal soleus muscle after sciatic nerve injury and subsequent re-innervation | [43] |
PP2A B56a | PP2A B56a downregulated | 133a upregulated | Canine heart failure model: myocytes | [207] |
CaMKII-dependent hyperphosphorylation of RyR2 | VF myocytes had increased reactive oxygen species and increased RyR oxidation | miR-1 upregulated | Canine post-myocardial infarction model | [208] |
Collagen upregulated | TGF-b1 and TGFbRII: upregulated | miR-133a or miR-590: downregulated | Canine model of acute nicotine exposure. Atrial fibrosis in vivo; cultured canine atrial fibroblasts in vitro | [209] |
miR-208 upregulated | miR-1 and miR-133a downregulated | Human MI compared to healthy adult hearts | [210] | |
Myogenic proteins, MyoD1, myogenin and Pax7 | Induced expression of MyoD1, myogenin and Pax7 several days after miR injection | Exogenous injection of miR-1, -133 and -206 promotes myotube differentiation | Regenerating injured mouse skeletal muscle | [211] |
Cyclin D1/ Sp1 | Cyclin D1/ Sp1 downregulated | miR-1/133 upregulated | Regenerating rat skeletal muscle | [212] |
PRP, source of pro-inflammatory cytokines | Stong upregulation of the mRNA of pro-inflammatory cytokines IL-1β and TGF-β1; stimulation of both inflammatory and myogenic pathways; elevated heat shock proteins and increased phosphorylation of αB-cristallin | Stimulated tissue recovery via increased myogenic regulators MyoD1, Myf5, Pax7, and IGF-1Eb (muscle isoform) together with SRF; acts via increased expression of miR-133a with reduced levels of apoptotic factors (NF-κB-p65 and caspase 3) | Regenerating flexor sublimis muscle of rats, 5 d after injury and treated with PRP | [66] |
Muscle degeneration | ||||
Pro-inflammatory cytokine TWEAK | TWEAK upregulated | miR-1-1, miR-1-2, miR-133a, miR-133b and miR-206 downregulated | Degenerating/wasting mouse skeletal muscle | [59] |
HMOX1 mediated by codependent inhibition of c/EBPδ binding to myoD promoter | HMOX1 inhibits differentiation of myoblasts and modulates miRNA processing | Downregulation of miR-1, miR-133a, miR-133b, and miR-206. | Degenerating/wasting mouse skeletal muscle | [60] |
HMOX1 effects partially reversed by enforced expression of miR-133b and miR-206 | Downregulation of MyoD, myogenin and myosin, and disturbed formation of myotubes. Upregulation of SDF-1 and miR-146a | |||
Dystrophic muscular disease | ||||
Circulating serum microRNAs | miR-1, miR-133a, and miR-206 highly abundant in Mdx serum | miR-1, miR-133a, and miR-206 downregulated or modestly upregulated in muscle | Muscle tissue from patients with Duchenne muscular dystrophy (Mdx) | [213] |
Laminin α2 chain deficiency | miR-1, miR-133a, and miR-206 are deregulated in laminin α2 chain-deficient muscle | Laminin α2 chain-deficient mouse | Congenital muscular dystrophy type 1A tissue | [214] |
Dystrophic process advances from prominent inflammation with necrosis and regeneration to prominent fibrosis | Deficiency in calpain leads initially to accelerated myofiber formation followed by depletion of satellite cells | Pax7-positive SCs highest in the fibrotic patient group; correlated with down-regulation of miR-1, miR-133a, and miR-206 | Muscle from Limb-girdle muscular dystrophy 2 type I patients | [215] |
Transgenic overexpression of miR-133a1 (in dystrophin point mutation Mdx mice) | Extensive overexpression in skeletal muscle, lesser increase in heart | Normal skeletal muscle and heart development | Mdx mice (model for human muscular dystrophy), extensor digitorum longus muscle | [216] |
miR-206 located in nuclear in both normal and DM1 tissues by in situ hybridization | Only miR-206 showed an over-expression in majority of DM1 patients | No change in expression of profiled miRs, miR-1, miR-133 (miR-133a/-133b), miR-181 (miR-181a/-181b/-181c) | Skeletal muscle (vastus lateralis) of from patients with myotonic dystrophy type 1 (DM1) | [217] |
FAPs facilitate myofiber regeneration | HDAC inhibitors can activate FAPs towards muscle regeneration | Inhibition of HDAC induces MyoD and BAF60C expression, which causes up-regulation of miR-1-2, miR-133, and miR-206 expression | Early stage disease dystrophic mouse muscles, regeneration of myofibres | [62] |
TDP-43 | TDP-43 interacts with miR-1/-206 isomers, but not miR-133 isomers | Depleted miR-1/-206 allow targets IGF-1 and HDAC4 to accumulate in ALS muscle | Mouse ALS model injured motor neurons and muscle | [33] |
Inflammation response in muscle | ||||
Inflammatory myopathies | Increased expression of TNFα | Associated with decreased expression of miR-1, miR-133a, and miR-133b | Inflammatory myopathies including dermatomyositis, polymyositis, and inclusion body myositis | [64] |
hBSMCs sensitized with IL-13 | Increased muscle RhoA | Reduction of muscle miR-133a | Sensitized human bronchial smooth muscle cells (hBSMCs) | [218] |
- Citation: Mitchelson KR, Qin WY. Roles of the canonical myomiRs miR-1, -133 and -206 in cell development and disease. World J Biol Chem 2015; 6(3): 162-208
- URL: https://www.wjgnet.com/1949-8454/full/v6/i3/162.htm
- DOI: https://dx.doi.org/10.4331/wjbc.v6.i3.162